MedTrace Logo

Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)

NCT05227534 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12500

Last updated 2022-07-06

No results posted yet for this study

Summary

PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.

Conditions

  • Cancer
  • Early Detection of Cancer
  • Circulating Cell-free DNA

Interventions

DEVICE

OverC multi-cancer detection blood test

Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Guangzhou Burning Rock Dx Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-03-01
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227534 on ClinicalTrials.gov